What is tesamorelin used for?

What the research literature says

Tesamorelin’s primary clinical application is HIV-associated lipodystrophy, established across the Falutz NEJM trial (PMID 18057338), the long-term safety extension (PMID 18690162), and the pooled phase 3 analysis (PMID 20554713). The 2 mg subcutaneous once-daily dose is the approved regimen. The Spooner pharmacotherapy review consolidates the clinical-pharmacology framework (PMID 22298602).

Secondary research applications include inflammatory-marker improvements in HIV patients with excess abdominal fat (PMID 21516030), metabolic-profile improvements correlating with visceral-fat reduction (PMID 22495074), and liver-enzyme improvements associated with visceral fat reduction (PMID 28832410). The Tomlinson drug-evaluation review covers the broader clinical-pharmacology framework (PMID 17086939).

The mechanism — GHRH-receptor agonism at the pituitary somatotroph cells with downstream GH and IGF-1 elevation — anchors research applications in GH-axis pharmacology more broadly. Tesamorelin is one of the most-extensively-characterised long-acting GHRH analogues with a substantial clinical-pharmacology dataset, making it useful as a comparison reference for newer GHRH-receptor research compounds.

Why this matters in research context

Tesamorelin’s FDA-approved status provides an unusually well-characterised pharmacological backdrop for research-supply protocols. The HIV-lipodystrophy indication is narrow but the underlying GH-axis pharmacology is broadly applicable. Researchers using tesamorelin in research-supply protocols can anchor experimental design to the substantial clinical-pharmacology dataset while operating within the research-use-only framework that governs the catalog supply form.

Related compounds

• Tesamorelin 10mg — the compound covered by this answer
• CJC-1295 No DAC 10mg — alternative GHRH analogue with shorter half-life

Related research questions

• What is the half-life of tesamorelin?
• Is tesamorelin FDA approved?
• Does tesamorelin raise IGF-1?

References

1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
2. Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008;22(14):1719-1728. [PMID 18690162]
3. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304. [PMID 20554713]
4. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012;46(2):240-247. [PMID 22298602]